A5045746656- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Renal and related cancers
- Cancer Treatment and Pharmacology
- Multiple and Secondary Primary Cancers
- Economic and Financial Impacts of Cancer
- Cancer survivorship and care
- Gastrointestinal Tumor Research and Treatment
- Bladder and Urothelial Cancer Treatments
- Gastric Cancer Management and Outcomes
- Cancer, Lipids, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Sarcoma Diagnosis and Treatment
- Head and Neck Cancer Studies
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Advanced Radiotherapy Techniques
- Hormonal and reproductive studies
- Ferroptosis and cancer prognosis
- Cardiac tumors and thrombi
- Radiomics and Machine Learning in Medical Imaging
- Ethics in Clinical Research
- Breast Cancer Treatment Studies
Dana-Farber Cancer Institute
2013-2024
Eastern Cooperative Oncology Group
2001-2023
ECOG-ACRIN Cancer Research Group
2017-2019
Fox Chase Cancer Center
2001-2018
Albert Einstein College of Medicine
2003-2018
The Ohio State University
2018
Pennsylvania State University
2018
Indiana University – Purdue University Indianapolis
2004-2017
Johns Hopkins University
2009-2017
Missouri Valley Cancer Consortium
2017
Because the optimal timing of institution antiandrogen therapy for prostate cancer is controversial, we compared immediate and delayed treatment in patients who had minimal residual disease after radical prostatectomy.
ContextSurvival benefit in the management of high-grade clinically localized prostate cancer has been shown for 70 Gy radiation therapy combined with 3 years androgen suppression (AST), but long-term AST is associated many adverse events.ObjectiveTo assess survival 3-dimensional conformal (3D-CRT) alone or combination 6 months patients cancer.Design, Setting, and PatientsA prospective randomized controlled trial 206 who were to receive 3D-CRT (n = 104) 102) from December 1, 1995, April 15,...
The abrogation of function the tumor-suppressor protein p53 as a result mutation its gene, TP53, is one most common genetic alterations in cancer cells. We evaluated TP53 mutations and survival patients with squamous-cell carcinoma head neck.A total 560 neck who were treated surgically curative intent enrolled our prospective multicenter, 7-year study. analyzed DNA from tumor specimens use Affymetrix chip Surveyor endonuclease denaturing high-performance liquid chromatography. Mutations...
Abstract Purpose: Nearly 2000 patients with stage IIB and III melanoma have participated in four multicenter, randomized trials, conducted by the Eastern Cooperative Oncology Group Intergroup, investigating adjuvant high-dose IFN-α 2b therapy. The objectives of this study were to update analyses each individual trial analyze prognostic factors treatment effects based on pooled data. Experimental Design: Survival disease status updated April 2001. Analysis using optimized statistical models...
Background: Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy. We performed a retrospective analysis Eastern Cooperative Oncology Group (ECOG) 5592, phase III randomized trial chemotherapy regimens for non-small-cell lung cancer (NSCLC), and compared outcomes in enrollees 70 years age older with those younger patients. Methods: ECOG carried out cisplatin plus either etoposide or paclitaxel chemotherapy-naïve NSCLC patients stages IIIB...
PURPOSE: We sought to evaluate the effects of chemotherapy-induced ovarian failure on bone loss and markers skeletal turnover in a prospective longitudinal study young women with breast cancer receiving adjuvant chemotherapy. PATIENTS AND METHODS: Forty-nine premenopausal stage I/II cancers chemotherapy were evaluated within 4 weeks starting (baseline), 6 12 months after dual-energy absorptiometry osteocalcin bone-specific alkaline phosphatase. Chemotherapy-induced was defined as negative...
Constitutive expression of telomerase prevents senescence and crisis by maintaining telomere homeostasis. However, recent evidence suggests that is dynamically regulated in normal cells also contributes to transformation independently net elongation. Here, we show suppression the catalytic subunit [human reverse transcriptase (hTERT)] abrogates cellular response DNA double strand breaks. Loss hTERT does not alter short-term integrity but instead affects overall configuration chromatin. Cells...
Pain is prevalent among patients with cancer, yet pain management patterns in outpatient oncology are poorly understood.A total of 3,123 ambulatory invasive cancer the breast, prostate, colon/rectum, or lung were enrolled onto this prospective study regardless phase care stage disease. At initial assessment and 4 to 5 weeks later, completed a 25-item measure pain, functional interference, other symptoms. Providers recorded analgesic prescribing. The index was calculated assess treatment...
Purpose Metastatic GI stromal tumor (GIST) is a life-threatening disease with no therapy of proven efficacy after failure imatinib and sunitinib. Regorafenib structurally unique inhibitor multiple cancer-associated kinases, including KIT platelet-derived growth factor receptor (PDGFR), broad-spectrum anticancer activity in preclinical early-phase trials. Because PDGFR-α remain drivers GIST resistance to sunitinib, we performed multicenter single-stage phase II trial regorafenib patients...
This study was designed to assess efficacy, safety, and predictors of response iniparib in combination with gemcitabine carboplatin early-stage triple-negative BRCA1/2 mutation-associated breast cancer.This single-arm phase II enrolled patients stage I IIIA (T ≥ 1 cm) estrogen receptor-negative (≤ 5%), progesterone human epidermal growth factor receptor 2-negative or cancer. Neoadjuvant (1,000 mg/m(2) intravenously [IV] on days 8), (area under curve 2 IV (5.6 mg/kg 1, 4, 8, 11) were...
Purpose The mammalian target of rapamycin inhibitor everolimus targets aberrant signaling through the PI3K/AKT/mammalian pathway, a mechanism resistance to anti-estrogen therapy in estrogen receptor (ER)-positive breast cancer. We hypothesized that plus selective ER downregulator fulvestrant would be more efficacious than alone ER-positive metastatic cancer resistant aromatase (AI) therapy. Patients and Methods This randomized, double-blind, placebo-controlled, phase II study included 131...
PURPOSE: To determine the response rate and toxicity profile of trastuzumab administered concurrently with weekly vinorelbine in women HER2-overexpressing advanced breast cancer. PATIENTS AND METHODS: Forty HER2-positive (+3 by immunohistochemistry, n = 30; +2 or positive, 10) cancer were enrolled onto a study (4 mg/kg × 1, 2 thereafter) (25 mg/m weekly, dose adjusted each week for neutrophil count). Eighty-two percent had received prior chemotherapy as part adjuvant (30%), metastatic (25%),...
PURPOSE: To identify factors that are prognostic for survival in patients with metastatic melanoma treated eight Eastern Cooperative Oncology Group (ECOG) trials conducted over the past 25 years. METHODS: We identified common, significant patient characteristics collected at baseline on 1,362 eligible inclusion a pooled analysis. Proportional hazards models were used to examine simultaneously effects of multiple covariates survival. RESULTS: Median was 6.4 months (95% confidence interval,...
To evaluate the role of adjuvant interferon alfa after complete resection locally extensive renal cell carcinoma.A total 283 eligible patients with pT3-4a and/or node-positive disease were randomly assigned radical nephrectomy and lymphadenectomy to observation or alfa-NL (Wellferon, Burroughs-Wellcome, Research Park, NC) given daily for 5 days every 3 weeks up 12 cycles. Patients stratified on basis pathologic stage. remained treatment until documented recurrence, excessive toxicity,...
Purpose To assess the efficacy of marine-derived alkaloid ecteinascidin 743 (ET-743) in patients with soft tissue sarcomas that progressed despite prior conventional chemotherapy and to characterize pharmacokinetic profiles ET-743 this patient population. Patients Methods Thirty-six previously treated sarcoma from three institutions received as a 24-hour continuous intravenous (IV) infusion at dose 1,500 μg/m 2 every 3 weeks. Pharmacokinetic studies were also performed. restaged two cycles...
A randomized phase III clinical trial of adjuvant active specific immunotherapy (ASI) with an autologous tumor cell-bacillus Calmette-Guérin (BCG) vaccine was conducted to determine whether surgical resection plus ASI more beneficial than alone in stage II and colon cancer patients.Patients (n = 412) (297 disease, 115 disease) were randomly allocated observation arm or a treatment which they received three weekly intradermal injections 10(7) irradiated cells beginning approximately 4 weeks...
PURPOSE: To evaluate the safety and efficacy of weekly docetaxel in women with metastatic breast cancer. PATIENTS AND METHODS: Twenty-nine were enrolled onto a study given at 40 mg/m 2 /wk. Each cycle consisted 6 weeks therapy followed by 2-week treatment break, repeated until disease progression or removal from for toxicity patient preference. Fifty-two percent patients had been previously treated adjuvant chemotherapy; 21% received prior chemotherapy cancer, 31% anthracyclines. All...
Purpose A phase II clinical trial was conducted to evaluate the feasibility and tolerability of a prime/boost vaccine strategy using vaccinia virus fowlpox expressing human prostate-specific antigen (PSA) in patients with biochemical progression after local therapy for prostate cancer. The induction PSA-specific immunity also evaluated. Patients Methods randomized by Eastern Cooperative Oncology group 64 eligible were randomly assigned receive four vaccinations fowlpox-PSA (rF-PSA), three...
Understanding the distinctive patterns of treatment-related dysfunction after alternative initial treatments for early prostate cancer (PC) may improve patients' choice treatment and later help them adjust to its consequences. We characterized time course complications while adjusting potentially confounding pretreatment factors hindering other observational studies.In a prospective cohort study 417 men we assessed urinary, bowel, sexual function from before primary 24 months after. To...
To define the rate of local recurrence (LR) and identify prognostic factors for LR patients with soft tissue sarcoma (STS) treated function-sparing surgery (FSS) without radiotherapy (RT).Between 1970 1994, 242 STS trunk extremity presented primary localized disease, 74 whom were FSS RT (31%). The median tumor size was 4 cm (range, 0.5 to 31 cm). There 40 grade 1 tumors 34 2 3 tumors. Median follow-up 126 months.The 10-year actuarial control 93% +/- 4%. Resection margin status a significant...